Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors

PURPOSE: Dose and schedule optimization of treatment with tyrosine kinase inhibitors is of utmost importance. On the basis of preclinical data, a phase I clinical trial of once weekly or once every 2 weeks administration of high-dose sunitinib in patients with refractory solid malignancies was condu...

Descripción completa

Detalles Bibliográficos
Autores principales: Rovithi, Maria, Gerritse, Sophie L., Honeywell, Richard J., ten Tije, Albert J., Ruijter, Rita, Peters, Godefridus J., Voortman, Jens, Labots, Mariette, Verheul, Henk M.W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368417/
https://www.ncbi.nlm.nih.gov/pubmed/30586316
http://dx.doi.org/10.1200/JCO.18.00725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368417/
https://www.ncbi.nlm.nih.gov/pubmed/30586316
http://dx.doi.org/10.1200/JCO.18.00725

Ejemplares similares